ABSTRACT NUMBER: ESOC2026A2331 PRECISION STROKE SECONDARY PREVENTION USING CYP2C19 GENOTYPE POINT-OF-CARE TESTING Authors: Radim Licenik, Charlotte Murray, Mohammad Haque, Mmua Ngwako, Suleman Mohammed, Mohsen Kermani, Silvie Davis, Dipraj Limbu, Martin Huncovsky Published: 2026 ABSTRACT AbstractBackground and aimsClopidogrel is a widely used drug for stroke secondary prevention following ischemic stroke and TIA. Over 25 % of the population is resistant to Clopidogrel due to reduced CYP2C19 enzyme activity. It makes Clopidogrel less effective or completely ineffective for secondary prevention. Rapid point-of-care testing (POCT) of Clopidogrel resistance identifies patients who need an alternative tailored treatment.MethodsCYP2C19 POCT was initially implemented for a group of following patients before starting or already on stroke secondary prevention with Clopidogrel: Young stroke patients, aged 16 – 55Recurrent stroke or TIA patientsPatient underwent mechanical thrombectomy or intravenous thrombolysisPatients with multiple severe cerebro-cardiovascular comorbiditiesPOCT was performed from March 2025 to January 2026. To detect the six most common alleles (*2, *3, *4, *8, *17 and *35) the Genedrive System was used. Based on the CYP2C19 genotype, patients were classified as normal, rapid, ultra-rapid, intermediate and poor metabolizers. Multidisciplinary team discussed the genotype results, metabolism, likely phenotype, implications of the results and made recommendations for further personalized management.ResultsA total of 76 patients were tested. The cohort included 34 young stroke patients (45 %). 26 Normal metabolisers (*1/*1), 18 rapid (*1/*17), 3 ultra-rapid (*17/*17), 21 intermediate (*1/*2, *2/*17), and 8 poor (*2/*2) metabolizers were detected. 29 patients (38 %), intermediate and poor metabolisers, required a change to alternative tailored stroke secondary prevention. 19 of these patients were started on Ticagrelor as an alternative.ConclusionsCYP2C19 POCT is a fast and efficient method for precise stroke secondary prevention.Conflict of interestNothing to disclose